The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...
The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...
The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...
Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could ...
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results